Status:
COMPLETED
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Taiwan, Inc.
Conditions:
Sleep Initiation and Maintenance Disorders
Primary Insomnia
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified release) compared to zolpidem IR (immediate release) in patients with primary insomnia.
Eligibility Criteria
Inclusion
- Diagnosis of primary insomnia based on DSM-IV criteria (307.42)
- Written informed consent has been obtained
Exclusion
- Patients with sleep apnea syndrome, narcolepsy, presence or suspicion of periodic leg movement or restless leg syndrome
- Patients with hepatic failure, myasthenia gravis, or hypersensitivity to zolpidem
- Patients who are known to be current drug or alcohol abuser or likely to concomitantly consume alcoholic beverages (more than 3 times/week)
- Patients who have received antihistamines or antipsychotics will not allow to discontinue the previous medication throughout the study
- Patients who are pregnant, lactating or intend to become pregnant during the study period
- Patients who have received antidepressants or anxiolytics will not allow to change the dose or discontinue the previous medication throughout the study
- Any clinically significant condition, which in the opinion of the investigator makes the patients unsuitable for the trial
- Participation in any clinical trial within 1 month prior to randomization
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT01181232
Start Date
October 1 2009
End Date
April 1 2011
Last Update
September 10 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tainan, Taiwan, 704
2
Taipei, Taiwan, 100